1Q FY3/2019 Supplementary Material

1.Financial Highlights

2014/3	2015/3	2016/3	2017/3	2018/3
165,347	181,844	219,239	223,468	241,274
18.6%	10.0%	20.6%	1.9%	8.0%
4,744	6,647	10,489	8,519	10,587
2.9%	3.7%	4.8%	3.8%	4.4%
1,901	2,778	6,329	4,638	6,104
1.2%	1.5%	2.9%	2.1%	2.5%
15,849	17,635	32,473	36,447	41,504
13.5%	13.6%	20.6%	20.4%	22.2%
	165,347 18.6% 4,744 2.9% 1,901 1.2% 15,849	165,347 181,844 18.6% 10.0% 4,744 6,647 2.9% 3.7% 1,901 2,778 1.2% 1.5% 15,849 17,635	165,347 181,844 219,239 18.6% 10.0% 20.6% 4,744 6,647 10,489 2.9% 3.7% 4.8% 1,901 2,778 6,329 1.2% 1.5% 2.9% 15,849 17,635 32,473	165,347 181,844 219,239 223,468 18.6% 10.0% 20.6% 1.9% 4,744 6,647 10,489 8,519 2.9% 3.7% 4.8% 3.8% 1,901 2,778 6,329 4,638 1.2% 1.5% 2.9% 2.1% 15,849 17,635 32,473 36,447

	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q
Net sales (Millions of yen)	43,133	48,895	54,476	58,346	59,305
YoY growth rate	8.6%	13.4%	11.4%	7.1%	1.6%
Operating profit (Millions of yen)	878	2,052	1,620	2,184	501
Operating margin	2.0%	4.2%	3.0%	3.7%	0.8%
Profit attributable to owners of parent (Millions of yen)	293	1,221	981	1,122	40
Return on sales	0.7%	2.5%	1.8%	1.9%	0.1%
Shareholder's equity (Millions of yen)	16,144	18,669	33,044	37,171	41,170
Equity ratio	11.9%	13.4%	20.2%	20.0%	21.0%

2.Dispensing Pharmacy Business

No.of pharmacies opened 37 29 27 42 Including M&A 4 1 5 21 No.of pharmacies at the end of each period 494 511 527 557 Net sales of dispenshing pharmacy business (Millions of yen) 145.957 157.999 190.874 189.327 20	2017/3 2018/3
No.of pharmacies at the end of each period 494 511 527 557	42 36
· · · · · · · · · · · · · · · · · · ·	21 13
Not sales of dispensing pharmacy business (Millions of yon) 445 057 457 000 400 074 400 007	557 585
Net sales of dispenshing pharmacy business (Millions of yen) 145,957 157,999 190,874 189,327 20	189,327 205,192
Sales per Pharmacy (Millions of yen) 304 314 367 349	349 359
No.of prescription (thousands) 11,090 11,695 12,301 12,949 1	12,949 13,739
Unit prices of prescription (yen) 12,954 13,330 15,297 14,382 1	14,382 14,739

	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q
No.of pharmacies opened	8	6	11	8	8
Including M&A	0	0	1	5	0
No.of pharmacies at the end of each period	498	512	533	564	589
Net sales of dispenshing pharmacy business (Millions of yen)	37,546	42,322	45,912	49,387	50,449
Sales per Pharmacy (Millions of yen)	75	82	86	88	85
No.of prescription (thousands)	2,858	2,990	3,126	3,356	3,483
Unit prices of prescription (yen)	12,964	13,962	14,518	14,547	14,234
	12,001	10,002	11,010	11,011	11,20

3. Consolidated Balance Sheet

					(Mi	illions of yen)
(As of the end of the period)	2014/3 1Q	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q
Assets						
Current assets						
Cash and deposits	17,631	29,087	19,971	32,297	25,402	34,510
Notes receivable-trade	1,206	1,236	246	73	135	357
Accounts receivable-trade	14,835	17,078	20,254	23,989	25,901	18,844
Electronically recorded monetary claims-operating	_	_	801	987	940	940
Merchandise and finished goods	14,128	16,121	18,000	19,743	23,625	25,925
Work in process	1,016	764	1,090	2,520	2,458	1,489
Raw materials and supplies	3,313	3,169	4,498	5,020	5,704	5,730
Other	3,063	3,269	4,015	3,927	4,517	2,948
Allowance for doubtful accounts	(8)	(9)	(11)	(8)	(9)	(5)
Total current assets	55,188	70,717	68,869	88,551	88,677	90,742
Non-current assets		•	•	•	•	·
Property, plant and equipment						
Buildings and structures, net	14,179	13,972	20,795	22,018	22,645	34,671
Land	14,806	15,327	17,126	17,937	18,166	19,397
Construction in progress	3,332	8,666	2,108	2,917	12,008	5,599
Other, net	6,370	5,887	9,549	11,528	15,387	15,780
Total property, plant and equipment	38,690	43,852	49,580	54,402	68,208	75,449
Intangible assets		•	•	•	•	ŕ
Goodwill	8,121	9,101	8,501	8,441	15,800	15,069
Other	1,926	1,787	1,660	1,591	2,194	2,557
Total intangible assets	10,048	10,889	10,162	10,033	17,994	17,627
Investments and other assets	•	•	•	•	•	·
Investment securities	1,081	941	1,223	907	1,014	18
Lease and guarantee deposits	6,852	7,020	7,039	7,008	7,060	7,436
Other	2,774	2,470	2,661	2,616	2,616	4,757
Total investments and other assets	10,708	10,432	10,924	10,531	10,691	12,211
Total non-current assets	59,446	65,175	70,666	74,967	96,894	105,287
Total assets	114,635	135,892	139,535	163,518	185,572	196,030

Note: The amounts for the previous fiscal years in this materials do not reflect the revisions of the accounting standards.

					(Mi	llions of yen)
(As of the end of the period)	2014/3 1Q	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q
Liabilities						
Current liabilities						
Notes payable-trade	2,830	2,047	_	_	_	_
Accounts payable-trade	28,312	35,079	36,955	44,328	43,779	46,211
Electronically recorded obligations-operating	_	_	1,760	2,948	2,190	4,858
Short-term loans payable	7,800	9,650	4,800	3,200	1,400	_
Current portion of bonds	185	7,000	_	7,000	_	_
Current portion of long-term loans payable	10,687	3,993	5,288	5,938	13,221	22,430
Income taxes payable	1,059	720	1,342	886	1,424	923
Provision for bonuses	958	1,038	1,130	1,241	1,403	1,555
Provision for directors' bonuses	1	1	_	_	_	_
Provision for sales rebates	219	153	167	4	_	_
Other	5,586	5,762	7,354	9,116	9,495	11,024
Total current liabilities	57,640	65,446	58,799	74,663	72,915	87,003
Non-current liabilities						
Bonds payable	14,000	7,000	7,000	_	_	_
Long-term loans payable	22,870	43,099	49,317	50,479	70,670	61,743
Provision for retirement benefits	427	_	_	_	_	-
Provision for directors' retirement benefits	1,208	868	908	877	973	1,017
Net defined benefit liability	_	575	957	1,205	1,341	1,551
Other	1,638	2,757	3,883	3,248	2,499	3,542
Total non-current liabilities	40,144	54,301	62,066	55,810	75,485	67,854
Total liabilities	97,784	119,748	120,866	130,474	148,400	154,858
Net assets						
Shareholders' equity						
Capital stock	3,953	3,953	3,953	3,953	3,953	3,953
Capital surplus	4,754	4,754	4,754	10,926	10,926	10,926
Retained earnings	8,041	9,632	12,844	18,252	22,234	26,457
Treasury shares	(2,253)	(2,154)	(3,062)	(44)	(46)	(47)
Total shareholders' equity	14,495	16,185	18,489	33,088	37,068	41,289
Accumulated other comprehensive income						

251

251

16,850

180

(222)

(41)

16,144

380

(200)

179

18,669

139,535

170

(214)

(44)

33,044

163,518

246

(142)

103

37,171

185,572

Total liabilities and net assets 114,635 135,892

Note:The amounts for the previous fiscal years in this materials do not reflect the revisions of the accounting standards.

Valuation difference on available-for-sale securities

Total accumulated other comprehensive income

Remeasurements of defined benefit plans

Non-controlling interests

Total net assets

(119)

(119)

41,171

196,030

4. Consolidated Statement of Income

Income taxes-deferred

Profit(loss) attributable to non-controlling interests note1

Profit attributable to owners of parent note2

Total income taxes

(Millions of yen) (For the Three-month Period) 2017/3 1Q 2018/3 1Q 2019/3 1Q 2014/3 1Q 2015/3 1Q 2016/3 1Q Net sales 39,733 43,133 48,895 54,476 58,346 59,305 Cost of sales 33,440 36,005 45,248 47,693 49,547 40,136 Gross profit 6,292 7,127 8,759 9,228 10,652 9,757 Selling, general and administrative expenses 5,220 6,248 6,706 7,607 8,468 9,256 Operating profit 1,071 878 2,052 1,620 2,184 501 Non-operating income Commission fee 28 29 33 34 37 14 Rent income 26 66 94 94 104 110 Insurance return 69 Other 54 60 48 46 55 53 Total non-operating income 108 157 176 246 197 178 Non-operating expenses Interest expenses 173 200 197 186 169 149 Commission fee 8 7 7 5 4 3 Rent expenses 75 68 79 86 Other 50 70 58 53 37 41 Total non-operating expenses 281 233 332 320 291 279 Ordinary profit 946 756 1,896 1,545 2,090 398 Extraordinary income Gain on sales of non-current assets 17 0 3 0 0 Gain on sales of investment securities 8 Total extraordinary income 17 3 8 0 0 Extraordinary losses Impairment loss 32 Total extraordinary losses 32 Profit before income taxes 931 757 1,896 2,090 406 1,548 Income taxes-current 787 871

(252)

534

18

378

592

(128)

464

293

1,046

(371)

675

1,221

779

(212)

567

981

1,389

(422)

967

1,122

(504)

367

(1)

40

Note1: From the 2016/3 1Q, the presentation of "Minority interests" was changed to "Profit attributable to non-controlling interests."

Note2: From the 2016/31Q, the presentation of "NET Income" was changed to "Profit attributable to owners of parent."

5.Business Segment Performance

					(M ²	lillions of yen)
	2014/3 1Q	2015/3 1Q	2016/3 1Q	2017/3 1Q	2018/3 1Q	2019/3 1Q
Dispensing pharmacy business						
Net sales	35,040	37,546	42,322	45,912	49,387	50,449
Segment profit	1,753	1,190	2,015	1,475	2,511	1,404
Pharmaceutical manufacturing and sales business						
Net sales	5,561	6,506	7,702	9,387	9,407	9,754
Segment profit	74	330	589	744	318	59
Medical Professional Staffing and Placement Business						
Net sales	1,284	1,499	2,087	2,588	3,107	3,217
Segment profit	283	327	441	440	601	401

6.Company Plofile

Trade Name

Headquarters	37F GranTokyo North Tower,1-9-1,Marunouchi,Chiyoda-Ku,100-6737 Tokyo
Capital	3,953.02 million yen
Total Number of Issued Shares	16,024,000 shares
Fiscal Year-end	March
Stock Exchange for Listing	Tokyo Stock Exchange(TSE) First Section
Securities Code	3341
Our Business	Management of health insurance dispensing chain pharmacies,
	manufacture and sales of generic drugs,
	employment placement and dispatching service of medical professionals,
	information provision and consulting
Number of pharmacies(As of June 30,2018)	589

NIHON CHOUZAI Co.,Ltd.